<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593109</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU-LCAR-L10D</org_study_id>
    <nct_id>NCT03593109</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in Relapsed or Refractory Lymphoma</brief_title>
  <official_title>A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Legend Biotech Co.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, dose escalation clinical study to evaluate the safety and
      efficacy of infusion of dual specificity CD19 and CD22 CAR-T cells in patients with relapsed
      and refractory B-cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD19-directed CAR-T cell therapy has shown promising results for the treatment of relapsed or
      refractory B-cell malignancies, CD19 and CD22 are proteins usually expressed on the surface
      of the lymphoma cells. The dual specificity CAR enables the T-cells to recognize and kill the
      tumor cell through recognition of CD19 and CD22.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of treatment related adverse events</measure>
    <time_frame>Day 1-100 days after injection</time_frame>
    <description>Assessed by CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Day 1-5 years after injection</time_frame>
    <description>Objective response include complete remission and partial remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Day 1-5 years after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Day 1-5 years after injection</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Copy numbers of CAR-T cells in patients</measure>
    <time_frame>Day 1-5 years after injection</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Lymphoma</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <arm_group>
    <arm_group_label>LCAR-L10D treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In LCAR-L10D treatment group, patients will be treated with dual specificity CD19 and CD22 CAR-T cells with a escalation approach, 4 CAR-T dosage will be tested in this study: 0.5×10^6, 1.5×10^6, 5.0×10^6 CAR-T cells/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy</intervention_name>
    <description>Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.</description>
    <arm_group_label>LCAR-L10D treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent could be acquired;

          2. Histological detection confirmed CD19/CD22 postive lymphoma;

          3. Received more than 2 lines of chemotherapy;

          4. Relapsed after auto-hematopoietic stem cell transplantation;

          5. Received standard chemotherapies including Rituximab (CD20+) and anthracycline agents;

          6. With measurable disease;

          7. Life expectation for more than 3 months;

          8. ECOG 0~2;

          9. Adequate organ function: EF≥50%; normal ECG; CCR≥60ml/min; ALT and AST&lt;2.5 × upper
             limitation of normal, T-BIL &lt;25umol/L; PT and APTT &lt; 2 × upper limitation of normal;
             SpO2 &gt; 92%;

         10. Blood test: ANC &gt; 1×10^9/L, Plt ≥ 75×10^9/L;

         11. At least 4 weeks intervals since the last treatment;

         12. Results of pregnant test should be negative, and agree to conception control during
             treatment and 1 year after CAR-T infusion;

        Exclusion Criteria:

          1. History of allergies to any component of the CAR-T cell therapy;

          2. Prior CAR T-cell or other genetically-modified T-cell therapy;

          3. History of another primary malignancy that has not been in control for at least 3
             years;

          4. Relapsed after allo-hematopoietic stem cell transplantation;

          5. Uncontrolled infection, Active HBV or HCV infection, HIV positive;

          6. With central nervous system (CNS) involvement;

          7. Severe heart disease, Q-T elongation history;

          8. History or presence of clinically relevant CNS pathology such as epilepsy, seizure,
             paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease,
             cerebellar disease, organic brain syndrome, or psychosis;

          9. Immunosuppressive agents or steroids in recent 2 week before recruitment;

         10. Women in pregnancy and lactation;

         11. Participated in any other clinical trail in recent 3 months;

         12. Other conditions that principle investigator considered may increase the risk of the
             patients or interference the results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aili He, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital of Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aili He, MD, PhD</last_name>
    <phone>86-29-87679459</phone>
    <email>heaili@mail.xjtu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Liu, MD</last_name>
    <phone>86-29-87679457</phone>
    <email>lieujie@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aili He, MD, PhD</last_name>
      <phone>86-29-87679459</phone>
      <email>heaili@mail.xjtu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jie Liu, MD</last_name>
      <phone>86-29-87679457</phone>
      <email>lieujie@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Aili He, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 7, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>June 4, 2019</last_update_submitted>
  <last_update_submitted_qc>June 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chimeric Antigen Receptor T cells</keyword>
  <keyword>CD19 and CD22</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

